

1 **Exploring novel risk loci for heart failure and the shared genetic etiology with**  
2 **blood lipids, blood pressure, and blood glucose: a large-scale multi-trait**  
3 **association analysis**

4

5 Yanchen Zhu <sup>1</sup>, Yahui Wang <sup>1</sup>, Zhaorui Cui <sup>1</sup>, Fani Liu <sup>1</sup>, Jiqiang Hu <sup>1§</sup>

6 <sup>1</sup>Cardiology Department, Dongfang Hospital Beijing University of Chinese Medicine, Beijing, China.

7

8 **Correspondence:**

9 Prof. Jiqiang Hu

10 Email: [hujiqiang@bucm.edu.cn](mailto:hujiqiang@bucm.edu.cn).

11 Phone: (+86) 13522675198.

12 ORCID: 0009-0008-4678-7220

13 Affiliations: Department of Cardiology, Dongfang Hospital, Beijing University of Chinese Medicine,

14 Fanggu Road, Beijing 100078, China.

1 **Exploring novel risk loci for heart failure and the shared genetic etiology with**  
2 **blood lipids, blood pressure, and blood glucose: a large-scale multi-trait**  
3 **association analysis**

4

5 **Keywords**

6 Heart failure, Blood lipids, Blood pressure, Blood glucose, Shared genetics, Multi-trait association  
7 analysis

8

9 **Abstract**

10 **Background:** The comprehensive exploration of genomic risk loci for heart failure (HF) remains  
11 constrained, and the genetic role of blood lipids (BL), blood pressure (BP) and blood glucose (BG) in  
12 HF has not been fully characterized.

13 **Methods:** We first assessed the global and local genetic correlations between HF and the quantitative  
14 traits of BL, BP, and BG. We then employed multi-trait association analysis and multi-trait  
15 colocalization analysis to identify novel and pleiotropic genomic risk loci for HF. Furthermore, we  
16 explored potential genes, pathways, tissues, and cells associated with HF involving BL, BP, and BG.  
17 Lastly, we investigated potential therapeutic targets for HF.

18 **Findings:** We found extensive global and local genetic correlations between HF and the traits of BL,  
19 BP, and BG. Multi-trait association analysis successfully identified 154 novel genomic risk loci for HF.  
20 Multi-trait colocalization analysis further revealed 46, 35, and 14 co-localized loci shared by HF with  
21 BL, BP, and BG, respectively. We found that the loci shared by HF with these traits rarely overlapped,  
22 indicating distinct shared mechanisms. Gene-mapping, gene-based, and transcriptome-wide  
23 association analyses prioritized noteworthy candidate genes (such as LPL, GRK5, and TNNC1) for  
24 HF. In enrichment analysis, HF exhibited comparable characteristics with cardiovascular traits and  
25 metabolic correlated to BL, BP, and BG. We provided genetic evidence for putative drugs, and  
26 highlighted 33 robust potential protein targets.

27 **Interpretation:** These findings will provide biological insights into the pathogenesis for HF, and  
28 benefit the development of preventive or therapeutic drugs for HF.

29

## 1 **Introduction**

2 Heart failure (HF) is a prominent public health issue. Global statistics indicate that HF impacts over 64  
3 million individuals, which contributes the major cause of cardiovascular hospitalization rates, mortality,  
4 and healthcare expenditures(1, 2). As the terminal state of cardiac diseases, HF is a polygenic disease  
5 and presents a more intricate genetic structure than other cardiometabolic disorders. Therefore,  
6 investigating the underlying genetic mechanisms of HF could enhance our etiological understanding of  
7 HF and facilitate the development of potential targets for intervention. However, the exploration of the  
8 genetic mechanisms of HF is still insufficient.

9 Previous studies have identified several genomic risk loci associated with HF(3, 4). However, further  
10 identification of risk loci for HF remains challenging due to the limited sample size. Therefore, it is  
11 necessary to employ advanced statistical genetics methods to investigate the association of potential  
12 loci with HF. Multi-trait joint analysis can borrow relevant information from multiple related traits and  
13 has become an effective statistical method to improve statistical power to identify novel genomic risk  
14 loci for target traits(5). In the clinical practice, dyslipidemia, elevated blood pressure (BP), and blood  
15 glucose (BG), are main risk factors for HF, and these abnormal statuses are highly prevalent among HF  
16 patients, exerting a substantial influence on disease progression(6).

17 Despite HF is an irreversible progressive disease, the abnormalities in blood lipids (BL), BP, and BG  
18 can be identified early and treated effectively with medications. Previous studies have reported that BL,  
19 BP, and BG have potential shared genomic loci with HF(7, 8). In addition, the present genetics  
20 association study of BL, BP, and BG exhibits a substantial sample size, demonstrating significant  
21 polygenic heritability and greater multitude of genomic loci in contrast to prior research. Therefore,  
22 their multi-trait joint analysis with HF can not only borrow information from these traits to deeply  
23 explore HF-related genetic variations, but also identify pleiotropic loci shared by HF with BL, BP, and  
24 BG.

25 In this study, we utilized the largest publicly available genome-wide association study (GWAS)  
26 summary statistics to perform multi-trait analysis between HF and the quantitative traits of BL, BP, and  
27 BG. Our study aims to achieve two primary objectives. Firstly, we aim to discover potential novel  
28 genomic risk loci for HF, elucidate its genetic mechanism, and explore potential drug targets. Secondly,  
29 we aim to investigate the shared genetic etiology basis for HF with BL, BP, and BG, and characterize  
30 the genetic roles of BL, BP, and BG in HF.

## 1 **Methods**

### 2 **1.Population samples and ethics**

3 Figure 1 presents a schematic overview of our study. In this study, we utilized GWAS summary  
4 statistics for a total of 12 traits. For each trait, we utilized the most recent and largest publicly available  
5 GWAS summary statistics from European ancestry individuals. The GWAS summary statistics for HF  
6 were obtained from the Heart Failure Molecular Epidemiology for Therapeutic Targets (HERMES)  
7 consortium, which combined data from 26 cohort-level GWAS comprising 47,309 cases and 930,014  
8 controls(3). The Global Lipids Genetics Consortium (GLGC) consortium provided summary statistics  
9 [high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total  
10 cholesterol (TC), and triglyceride (TG)] (N= 1,320,016) of BL(9), and additional summary statistics  
11 [apolipoprotein A1(APOA1) (N= 393,193) and apolipoprotein B(APOB) (N= 439,214)] for BL traits  
12 were from UK Biobank(10). The GWAS summary statistics for BP traits [systolic blood pressure (SBP),  
13 diastolic blood pressure (DBP), and pulse pressure (PP)] were used from a meta-analysis study of UK  
14 Biobank (N= 458,577) and the International Consortium of Blood Pressure genetics (ICBP) (N=  
15 299,024, across 77 cohorts)(11). For BG, the summary statistics [fasting glucose (FG) (N=314,916) and  
16 hemoglobin A1c (HbA1c) (N=344,182)] were obtained from the UK Biobank-Neale lab(12). The  
17 supplementary Table 1 provides access to the specific details of each GWAS summary statistics.

### 18 **2.Statistical analysis**

19 The GWAS summary statistics underwent genotypic quality control measures. Supplement Methods  
20 provide more comprehensive description of these analytical procedures.

21 Both linkage disequilibrium score regression (LDSC)(13) and high-Definition Likelihood (HDL)(14)  
22 were conducted to evaluate heritability of each trait and the genetic correlation between HF and the  
23 quantitative traits of BL, BP, and BG. Latent causal variable model (LCV)(15) was employed to further  
24 evaluate the genetic causality proportion between HF and these traits. Given the intricate genetic  
25 structure of each region, we employed local analysis of [co]variant association (LAVA)(16) to examine  
26 local genetic correlation. To correct for multiple testing for above statistical analyses, we applied the  
27 Benjamini-Hochberg false discovery rate (FDR) approach, with the threshold set at 0.05.

28 We utilized multi-trait analysis of GWAS (MTAG)(5) to identify novel genomic risk loci for HF by  
29 leveraging the interrelationships among pairwise traits exhibiting significant genetic correlation. To  
30 assess the overall inflation resulting from the violation of the homogeneous assumption in MTAG

1 analysis, we computed the maximum FDR (maxFDR), which evaluate the overall inflation due to  
2 violation of the homogeneous assumption. The genome-wide significance threshold for  $HF_{MTAG}$  was  
3 determined to be  $P < 5 \times 10^{-8}$ . We further employed the Functional Mapping and Annotation of Genetic  
4 Associations (FUMA)(17) to characterize significant genomic loci. FUMA identified independent  
5 significant single nucleotide variants (SNVs) with a genome-wide significant and a linkage  
6 disequilibrium (LD) measure of  $r^2 \leq 0.6$ . Lead SNVs were determined by selecting independent  
7 significant SNVs that were not in LD with each other at  $r^2 \leq 0.1$ . Risk loci were defined by  
8 combining lead SNVs that physically overlapped or had LD blocks within 250 kb apart. FUMA  
9 additionally provided functional annotations such as ANNOVAR analysis, combined annotation  
10 dependent depletion (CADD) scores, and RegulomeDB scores. Variants with a CADD score exceeding  
11 12.37 were deemed potentially deleterious. To identify shared causal variants within each genomic  
12 locus across traits, hypothesis prioritization in multi-trait colocalization (HyPrColoc)(18) analysis was  
13 conducted based on genomic risk loci of  $HF_{MTAG}$ . The colocalized locus was considered if the posterior  
14 probability exceeded 0.7.

15 Based on MTAG results, we conducted a comprehensive investigation into the underlying shared  
16 biological mechanisms for HF with BL, BP, and BG. In order to identify potential genes associated  
17 with HF, a combination of gene-mapping, multi-marker analysis of genomic annotation (MAGMA)(19),  
18 and transcriptome-wide association analysis (TWAS)(20) methods were employed. The threshold for  
19 FDR.P correcting multiple testing was set at 0.05. Furthermore, we elucidated the biological pathways  
20 by conducting gen-set enrichment analyses using the GO and KEGG databases. In addition, we used  
21 the DESE (driver tissue estimation by selective expression) approach implemented in  
22 phenotype-cell-gene association analysis (PCGA)(21-24) website to further explore the tissue/cell  
23 types specificity and similar phenotypes for  $HF_{MTAG}$ .

### 24 **3.Genomics-driven drug discovery**

25 To further enhance gene-driven drug discovery for HF, we utilized the Genome for Repositioning drugs  
26 (GREP)(25) software to determine the clinical indication categories and the enrichment of candidate  
27 effector genes in drug repositioning. GREP conducts Fisher's exact tests to detect enrichment of a gene  
28 set within genes targeted by drugs currently in use or previously developed for the specific clinical  
29 indication category (Anatomical Therapeutic Chemical Classification System [ATC]). Furthermore,  
30 proteome-wide mendelian randomization (MR) was utilized to identify potential therapeutic plasma

1 protein targets for HF [UK Biobank Pharma Proteomics Project (UKB-PPP)(26), and deCODE  
2 genetics(27)]. The primary analysis was employed using the inverse variance weighted method, and all  
3 results underwent FDR correction (FDR.P<0.05). The steiger test was conducted to assess whether the  
4 MR results were affected by potential reverse causality. The MR-Egger regression intercept test and  
5 Cochran's Q test were used to respectively assess the presence of pleiotropy and heterogeneity of the  
6 results. Bayesian colocalization analysis was utilized to examine whether the observed significant  
7 protein-disease pairs were driven by single causal SNV in the LD region(28). Specifically, we set the  
8 threshold of posterior probability hypotheses 4(the protein and HF were driven by single causal SNV)  
9 at 0.7. Based on MR and colocalization, phenome-wide MR analysis was conducted to investigate the  
10 pleiotropic or side effects of the protein targets (FDR.P<0.05).

## 11 **Results**

### 12 **1.Genetic correlation and genetic causality proportion**

13 LDSC results showed that BG (FG, HbA1c), BP (SBP, DBP, and PP), and TC exhibited significant  
14 positive genetic correlations with HF. Conversely, HDL-C and APOA1 displayed significant negative  
15 genetic correlations (Supplementary Table 2; Fig. 2). The results pertaining to HDL exhibit a notable  
16 level of congruity with the findings of LDSC (Supplementary Table 3; Fig. 2). LAVA discovered a total  
17 of 366 significant bivariate local genetic correlations (FDR.P<0.05) for HF with BL, BP, and BG at 224  
18 specific regions (Supplementary Table 4; Fig. 2). The present study reveals a general pattern in the  
19 local genetic correlations for HF with HDL-C, APOA1, and APOB, indicating a notable inclination  
20 towards negative correlations. Conversely, other traits exhibit a tendency towards positive correlations,  
21 aligning with the direction of their respective global genetic correlations. It should be noted that the  
22 coexistence of both negative and positive local genetic correlations suggests a multifaceted impact.

23 The LCV analyses demonstrated significant associations between HF and FG ( $|GCP| = 0.65$ , FDR.P =  
24 0.015), SBP ( $|GCP| = 0.33$ , FDR.P = 0.002), DBP ( $|GCP| = 0.38$ , FDR.P =  $7.91 \times 10^{-5}$ ) (Supplementary  
25 Table 5; Fig. 2), suggesting a potential genetic causal association for HF with FG, SBP, and DBP.

### 26 **2. Multi-trait association analysis**

27 Multi-trait association analyses combining HF with BL, BP, and BG, respectively, significantly  
28 increased the effective sample sizes and heritability of HF. Specifically, the polygenic heritability  
29 exhibited an impressive 2.02-, 1.83-, and 1.3-fold escalation for each respective HF<sub>MTAG</sub> consideration.  
30 Accompanied by max-FDR values of 0.046, 0.032, and 0.029 (Table 1), respectively, showed no

1 indication of inflation, thereby confirming the reliability of our methodology and findings. We  
2 successfully identified 93, 48 and 40 genomic risk loci from 486, 109 and 97 independent  
3 genome-wide significant SNVs for HF<sub>BL</sub>, HF<sub>BP</sub>, and HF<sub>BG</sub>, of which 85, 41, and 31 are novel risk loci  
4 for HF (Supplementary Table 6-12; Fig. 3). The HyPrColoc further identified 46, 35, and 14 pleiotropic  
5 loci that exhibited evidence of colocalization, indicating the widely distribution of shared genomic  
6 risk loci for HF with BL, BP, and BG (Supplementary Table 13-15).  
7 Furthermore, ANNOVAR offered notable variants' annotation information regarding these loci  
8 (Supplementary Table 16-18). For instance, we discovered 117 (2.8%) of 4188 genome-wide  
9 significant SNVs from HF<sub>BL</sub> loci are exons, 77 of which are located in protein-coding genes (35  
10 synonymous SNVs, 42 nonsynonymous SNVs). Further annotation by Combined  
11 Annotation-Dependent Depletion (CADD) scores predicted that 186 SNVs were deleterious (CADD  
12 score > 12.37). We noted several novel genomic risk loci and variants of interest. The most significant  
13 risk locus is located at region 8p21.3, and its index variant rs144958026 ( $P = 5.51 \times 10^{-65}$ ) is an intronic  
14 variant of LPL gene which encoding lipoprotein lipase. The next significant locus is located at region  
15 11q12.2, whose index variant rs174551 ( $P = 6.92 \times 10^{-50}$ ) is located in the 5-UTR of genes FADS1 and  
16 FADS2. Fatty acid desaturase (FADS) genes encode the fatty acid desaturase enzyme that is mainly  
17 responsible for regulating the biosynthesis of unsaturated fatty acids in the fatty acid metabolic  
18 pathway. In addition, rs34312154 ( $P = 3.38 \times 10^{-09}$ ) in region 11p11.2 has the highest CADD score of 31.  
19 We also noted four index variants that fell in the exonic region, including rs61749613 ( $P = 3.62 \times 10^{-9}$ ;  
20 gene = VCAN), rs55707100 ( $P = 2.61 \times 10^{-15}$ ; gene = MAP1A), rs1800961 ( $P = 4.06 \times 10^{-16}$ ; gene =  
21 HNF4A), and rs9935936 ( $P = 1.72 \times 10^{-9}$ ; gene = GNAO1:RP11-441F2.5).  
22 Notably, by combining MTAG analysis for HF with BL, BP and BG, we discovered a total of 165 HF  
23 risk loci, of which 154 of these identified loci were novel discoveries in relation to HF. By comparing  
24 locus reported in GWAS catalog (Supplementary Table 19-21), we found that a total of 143 loci have  
25 not been reported before. Interestingly, there was only a 6.1% overlap between the loci related to HF<sub>BL</sub>,  
26 HF<sub>BP</sub>, and HF<sub>BG</sub>, indicating that these three with different mechanisms that contribute to the effects on  
27 HF.

### 28 **3. Gene-based and transcriptome-wide association analysis**

29 FUMA mapped 1466 [including 1251 positional mapped genes, 327 expression quantitative trait loci  
30 (eQTL) mapped genes and 540 3D Chromatin Interaction mapped genes], 486 (including 406

1 positional mapped genes, 108 eQTL mapped genes and 145 3D Chromatin Interaction mapped genes),  
2 500 (including 435 positional mapped genes, 113 eQTL mapped genes and 190 3D Chromatin  
3 Interaction mapped genes) genes for HF<sub>BL</sub>, HF<sub>BP</sub>, and HF<sub>BG</sub>, respectively (Supplementary Table 22-24).  
4 We obtained a total of 2444 candidate genes, of which only 5.8% overlapped.

5 The MAGMA gene-based analysis found a total of 910, 703, and 398 genes significantly associated  
6 with HF<sub>BL</sub>, HF<sub>BP</sub>, and HF<sub>BG</sub> (FDR.P<0.05) (Supplementary Table 25-27). We obtained a total of 1539  
7 candidate genes, of which only 23.8% overlapped.

8 Combined with tissue-specific eQTL data (GTEx v8)(29) for whole blood, artery-aorta, coronary,  
9 heart-atrial appendage, and left ventricle, TWAS analysis revealed 248, 71, 53 genes for HF<sub>BL</sub>, HF<sub>BP</sub>,  
10 and HF<sub>BG</sub> (FDR.P<0.05) (Supplementary Table 28-30). Among a total of 359 candidate genes, only a  
11 minimal proportion of 3.34% exhibited overlapping associations.

12 In summary, the results obtained from the parallel gene-level analyses are consistent with the findings  
13 of the preceding SNV-level analyses, indicating a limited overlap among the genes associated with  
14 HF<sub>BL</sub>, HF<sub>BP</sub>, and HF<sub>BG</sub> (Supplementary Fig. 1). This provides additional support to the concept that BL,  
15 BP, and BG exert their impact on HF through separate mechanisms.

#### 16 **4. Gene-set enrichment**

17 The MAGMA gene-set analysis indicated that the predominant biological processes of 87 pathways  
18 implicated in the interaction between HF and BL primarily revolve around lipid metabolism.  
19 Furthermore, we identified 43 HF<sub>BP</sub> and 16 HF<sub>BG</sub> pathways (Supplementary Table 31-34;  
20 Supplementary Fig. 2). The results demonstrate that the biological processes involved in the association  
21 between HF and BP are significantly linked to vasculature and muscle development, while the  
22 association between HF and BG primarily revolves around hexokinase activity and lipid metabolism.

#### 23 **5. Phenotype-cell-gene specificity association analysis**

24 We found that arterial, adipose, and lung tissues displayed significant associations with HF<sub>MTAG</sub>. The  
25 tissues that exhibited the top 3 strongest correlations with HF<sub>BL</sub> were adipose-visceral omentum,  
26 artery-coronary, and adipose-subcutaneous (Supplementary Table 34-36; Supplementary Fig. 3). For  
27 HF<sub>BP</sub>, the top 3 significant associations were observed in artery-coronary, artery-tibial, and lung. And  
28 HF<sub>BG</sub> demonstrated a strong correlation with artery-coronary, subcutaneous adipose, and artery-tibial.  
29 Among 2,214 human single cell types, macrophages were identified as pivotal cell types for HF<sub>BL</sub>,  
30 endothelial cells for HF<sub>BP</sub>, and ACE2-expressing AT2 cells exhibited the most notable association with



1 HF<sub>BG</sub> (Supplementary Table 37-39; Supplementary Fig.4). Through the examination of phenotypic  
2 similarities in 1,588 unique phenotypes, our findings align with established biological knowledge. As  
3 expected, HF<sub>BL</sub>, HF<sub>BP</sub>, and HF<sub>BG</sub> exhibited comparable characteristics with cardiovascular traits and  
4 metabolic traits correlated to BL, BP, and BG (Supplementary Table 40-42; Supplementary Fig. 5).

#### 5 **6.Existing drug effects for heart failure**

6 Using GREP software for enrichment of significant HF-related genes obtained from gene-mapping,  
7 MAGMA, and TWAS analyses, we identified significant enrichment genes (ABCA1, APOB, LPL,  
8 PPARD, PPARG, and THRA) for HF<sub>BL</sub> in drug targets of the cardiovascular lipid-modifying drug  
9 targets (ATC C10 drugs), which encode targets for probucol, mipomersen, clofibrate, gemfibrozil,  
10 bezafibrate, and dextrothyroxine (Supplementary Table 43). HF<sub>BP</sub> genes demonstrated significant  
11 enrichment within the cardiovascular beta-blocking drug targets (ATC C07 drugs), incorporating  
12 ADRA1B and KCNH2 genes that encode targets for labetalol and sotalol (Supplementary Table 43).  
13 And HF<sub>BG</sub> genes exhibited a significant enrichment within drug targets for systemically used antivirals  
14 (ATC J05 drugs), which included the ADORA2B and CES1 genes, the encoding targets for vidarabine  
15 and oseltamivir (Supplementary Table 43).

#### 16 **7.Plasma protein targets for heart failure**

17 We performed two-sample MR using plasma protein quantitative trait loci (pQTL) statistics from the  
18 UK Biobank Pharma Proteomics Project (UKB-PPP)(26) and deCODE(27) genetics with HF<sub>MTAG</sub>  
19 statistics to evaluate protein targets for primary prevention for HF. We identified a total of 33 protein  
20 targets that satisfied the statistical significance of both MR (FDR.P<0.05) and colocalization  
21 (PP.H4>0.7) support in at least one cohort, and there was no reverse causal association by steiger  
22 testing (Fig. 4). Sensitivity analyses also showed that there was no pleiotropy or obvious heterogeneity.  
23 Among the 4907 pQTL for drug target proteins from deCODE, our results identified a total of 16  
24 plasma proteins with potential causal associations with HF risk (Supplementary Table 44-46). These  
25 proteins were supported by MR (FDR.P < 0.05) and colocalization (PP.H4>0.7) analyses, and no  
26 reverse causal association was indicated by steiger test. Among them, GSTM4, NADK, and NPPB  
27 were replicated in the UKB-PPP cohort (FDR.P < 0.05; PP.H4>0.7; Steiger.P < 0.05) and had  
28 consistent effect directions. GSTA1 and LILRA5 were supported by colocalization in the UKB-PPP  
29 cohort (PP.H4>0.7), and the MR results showed nominal significance (P<0.05). INHBC, despite having  
30 a consistent direction of effect in the UKB-PPP cohort, was not supported by MR and colocalization.

1 The remaining proteins (APOA4, KPNA2, ALDH2, CSK, HEXIM2, NMT1, NPPA, ULK3, ALDH6A1,  
2 PFKM) are only available in the deCODE cohort due to strict instrumental variable filtering conditions.  
3 For 2941 pQTL in UKB-PPP, additional 17 protein targets (FDR.P < 0.05; PP.H4 > 0.7; Steiger.P < 0.05)  
4 were identified (Supplementary Table 47-49). Among them, NCAN, PLTP, and DLL1 received  
5 colocalization support in the previous deCODE cohort (PP.H4 > 0.7), and the MR results all showed  
6 nominal significance (P < 0.05). PLG did not find MR significance in the deCODE cohort but was  
7 supported by colocalization. DLK1 was not supported by MR and colocalization. The remaining  
8 proteins (APOA2, ATRAAID, CELSR2, CTRL, HYOU1, LPL, CELSR2, FES, SH2B3, SPINK8,  
9 TJAP1, WASHC3, ZBTB17) could not be replicated in the deCODE cohort due to lack of instrumental  
10 variables. In addition, further phenome-wide MR analysis revealed that no side effects for the majority  
11 of identified protein targets were observed, while simultaneously indicating potential therapeutic  
12 benefits for other significant medical conditions (Supplementary Results; Supplementary Fig. 6-7).

### 13 **Discussion**

14 Multi-trait association analysis for HF with BL, BP, and BG significantly improved the statistical  
15 power in identification of novel genomic risk loci for HF. We discovered 154 novel HF loci, of which  
16 143 have not been reported previously. We further explored the shared genetic etiology, including  
17 potential genes, pathways, tissues, and cells for HF with these traits. The novel loci we have identified  
18 hold promise as potential targets for drug development or therapeutic interventions. Furthermore,  
19 bioinformatics analyses provide genetic evidence for putative drug effects and novel protein targets of  
20 HF (Supplementary Discussion).

21 In this study, our findings suggest that there is minimal overlap between the risk loci or genes  
22 associated with HF<sub>BL</sub>, HF<sub>BP</sub>, and HF<sub>BG</sub>, indicating that the risk of HF caused by these factors appears to  
23 be independent, with distinct biological mechanisms. Consequently, the combination therapeutic  
24 strategy targeting HF with BL, BP, and BG may offer additive and diverse benefits.

25 The 154 risk loci include some noteworthy HF-related genes. Lipoprotein lipase (LPL)-mediated  
26 hydrolysis of circulating lipoproteins into fatty acids (FA) is thought to be the primary source of FA  
27 utilization by the heart(30). Studies have shown that mice with cardiac LPL deficiency develop HF as  
28 they age and are unable to respond normally to increased afterload. In addition, LPL-deficient mice  
29 result in a reduction in HDL-C of more than 50%(30). The significance of G protein-coupled receptor  
30 kinase 5 (GRK5) as a key regulator of pathological cardiac hypertrophy has been documented,

1 rendering it a potential therapeutic target for HF. GRK5 was found to be upregulated in the  
2 myocardium of individuals with HF, as well as to promote maladaptive cardiac hypertrophy in animal  
3 models(31). Furthermore, an experimental and pharmacogenomic research showed the  
4 pharmacogenomic interaction between GRK5 and beta-blocker therapy, wherein the presence of the  
5 GRK5-Leu41 polymorphism was linked to a reduction in mortality rates among African American  
6 individuals afflicted with HF or cardiac ischemia(32). TNNC1 (Troponin C1, Slow Skeletal and  
7 Cardiac Type) is a protein coding gene. Diseases associated with TNNC1 include cardiomyopathy,  
8 familial hypertrophic and cardiomyopathy(33). TNNC1 is mainly related to striated muscle contraction.  
9 The inotropic drug levosimendan, which targets TNNC1, is a common drug for HF.  
10 We acknowledge some limitations. Our analyzes were limited to individuals of European ancestry and  
11 the results may not be generalizable to other ancestry. Additionally, we excluded all rare variants (MAF  
12 < 1%) from the MTAG analysis and therefore from all subsequent analyses. Therefore, we may not be  
13 able to identify rare variants with large effects. In MR analyses, we exclusively utilized cis-regulatory  
14 regions as instrumental variables, which may mitigate horizontal pleiotropy to some extent and result in  
15 reduced statistical efficacy. Lastly, our inquiry was restricted to identifying and validating pQTL data  
16 utilizing accessible instrumental variables, potentially neglecting alternative therapeutic targets.

## 17 **Conclusion**

18 In conclusion, this multi-trait association study provides important insights to the risk loci for HF and  
19 the shared genetic etiology for HF with BL, BP, and BG. Additionally, it highlights existing drugs and  
20 potential novel protein targets for HF therapy. These findings will provide biological insights into the  
21 pathogenesis for HF, and benefit the development of preventive or therapeutic drugs for HF.

## 1 **Reference**

- 2 1. Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and  
3 years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a  
4 systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018;392(10159):1789-858.
- 5 2. Ziaecian B, Fonarow GC. Epidemiology and aetiology of heart failure. *Nat Rev Cardiol*.  
6 2016;13(6):368-78.
- 7 3. Shah S, Henry A, Roselli C, Lin H, Sveinbjornsson G, Fatemifar G, et al. Genome-wide  
8 association and Mendelian randomisation analysis provide insights into the pathogenesis of heart  
9 failure. *Nat Commun*. 2020;11(1):163.
- 10 4. Joseph J, Liu C, Hui Q, Aragam K, Wang Z, Charest B, et al. Genetic architecture of heart failure  
11 with preserved versus reduced ejection fraction. *Nat Commun*. 2022;13(1):7753.
- 12 5. Turley P, Walters RK, Maghzian O, Okbay A, Lee JJ, Fontana MA, et al. Multi-trait analysis of  
13 genome-wide association summary statistics using MTAG. *Nat Genet*. 2019;51(7):1190.
- 14 6. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC  
15 guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for  
16 the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of  
17 Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur J*  
18 *Heart Fail*. 2012;14(8):803-69.
- 19 7. Kononov S, Azarova I, Klyosova E, Bykanova M, Churnosov M, Solodilova M, et al.  
20 Lipid-Associated GWAS Loci Predict Antiatherogenic Effects of Rosuvastatin in Patients with  
21 Coronary Artery Disease. *Genes (Basel)*. 2023;14(6).
- 22 8. Levin MG, Tsao NL, Singhal P, Liu C, Vy HMT, Paranjpe I, et al. Genome-wide association and  
23 multi-trait analyses characterize the common genetic architecture of heart failure. *Nat Commun*.  
24 2022;13(1):6914.
- 25 9. Graham SE, Clarke SL, Wu KH, Kanoni S, Zajac GJM, Ramdas S, et al. The power of genetic  
26 diversity in genome-wide association studies of lipids. *Nature*. 2021;600(7890):675-9.
- 27 10. Richardson TG, Sanderson E, Palmer TM, Ala-Korpela M, Ference BA, Davey Smith G, et al.  
28 Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of  
29 coronary heart disease: A multivariable Mendelian randomisation analysis. *PLoS Med*.  
30 2020;17(3):e1003062.

- 1 11. Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, et al. Genetic analysis  
2 of over 1 million people identifies 535 new loci associated with blood pressure traits. *Nat Genet.*  
3 2018;50(10):1412-25.
- 4 12. Neale lab team. GWAS Results Round 2. <http://www.nealelab.is/ukbiobank/> (2018).
- 5 13. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Schizophrenia Working Group of the  
6 Psychiatric Genomics C, et al. LD Score regression distinguishes confounding from polygenicity in  
7 genome-wide association studies. *Nat Genet.* 2015;47(3):291-5.
- 8 14. Ning Z, Pawitan Y, Shen X. High-definition likelihood inference of genetic correlations across  
9 human complex traits. *Nat Genet.* 2020;52(8):859-64.
- 10 15. O'Connor LJ, Price AL. Distinguishing genetic correlation from causation across 52 diseases and  
11 complex traits. *Nat Genet.* 2018;50(12):1728-34.
- 12 16. Werme J, van der Sluis S, Posthuma D, de Leeuw CA. An integrated framework for local genetic  
13 correlation analysis. *Nat Genet.* 2022;54(3):274-82.
- 14 17. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of  
15 genetic associations with FUMA. *Nat Commun.* 2017;8(1):1826.
- 16 18. Foley CN, Staley JR, Breen PG, Sun BB, Kirk PDW, Burgess S, et al. A fast and efficient  
17 colocalization algorithm for identifying shared genetic risk factors across multiple traits. *Nat Commun.*  
18 2021;12(1):764.
- 19 19. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of  
20 GWAS data. *PLoS Comput Biol.* 2015;11(4):e1004219.
- 21 20. Gusev A, Ko A, Shi H, Bhatia G, Chung W, Penninx BW, et al. Integrative approaches for  
22 large-scale transcriptome-wide association studies. *Nat Genet.* 2016;48(3):245-52.
- 23 21. Xue C, Jiang L, Zhou M, Long Q, Chen Y, Li X, et al. PCGA: a comprehensive web server for  
24 phenotype-cell-gene association analysis. *Nucleic Acids Res.* 2022;50(W1):W568-W76.
- 25 22. Gold JI, Gao E, Shang X, Premont RT, Koch WJ. Determining the absolute requirement of G  
26 protein-coupled receptor kinase 5 for pathological cardiac hypertrophy: short communication. *Circ Res.*  
27 2012;111(8):1048-53.
- 28 23. Li M, Jiang L, Mak TSH, Kwan JSH, Xue C, Chen P, et al. A powerful conditional gene-based  
29 association approach implicated functionally important genes for schizophrenia. *Bioinformatics.*  
30 2019;35(4):628-35.

- 1 24. Jiang L, Miao L, Yi G, Li X, Xue C, Li MJ, et al. Powerful and robust inference of complex  
2 phenotypes' causal genes with dependent expression quantitative loci by a median-based Mendelian  
3 randomization. *Am J Hum Genet.* 2022;109(5):838-56.
- 4 25. Sakaue S, Okada Y. GREP: genome for REPositioning drugs. *Bioinformatics.*  
5 2019;35(19):3821-3.
- 6 26. Sun BB, Chiou J, Traylor M, Benner C, Hsu YH, Richardson TG, et al. Plasma proteomic  
7 associations with genetics and health in the UK Biobank. *Nature.* 2023;622(7982):329-38.
- 8 27. Ferkingstad E, Sulem P, Atlason BA, Sveinbjornsson G, Magnusson MI, Styrismisdottir EL, et al.  
9 Large-scale integration of the plasma proteome with genetics and disease. *Nat Genet.*  
10 2021;53(12):1712-21.
- 11 28. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al. Bayesian  
12 test for colocalisation between pairs of genetic association studies using summary statistics. *PLoS*  
13 *Genet.* 2014;10(5):e1004383.
- 14 29. Consortium GT, Laboratory DA, Coordinating Center -Analysis Working G, Statistical Methods  
15 groups-Analysis Working G, Enhancing Gg, Fund NIHC, et al. Genetic effects on gene expression  
16 across human tissues. *Nature.* 2017;550(7675):204-13.
- 17 30. Goldberg IJ. 2017 George Lyman Duff Memorial Lecture: Fat in the Blood, Fat in the Artery, Fat  
18 in the Heart: Triglyceride in Physiology and Disease. *Arterioscler Thromb Vasc Biol.*  
19 2018;38(4):700-6.
- 20 31. Hullmann JE, Grisanti LA, Makarewich CA, Gao E, Gold JI, Chuprun JK, et al. GRK5-mediated  
21 exacerbation of pathological cardiac hypertrophy involves facilitation of nuclear NFAT activity. *Circ*  
22 *Res.* 2014;115(12):976-85.
- 23 32. Liggett SB, Cresci S, Kelly RJ, Syed FM, Matkovich SJ, Hahn HS, et al. A GRK5 polymorphism  
24 that inhibits  $\beta$ -adrenergic receptor signaling is protective in heart failure. *Nat Med.* 2008;14(5):510-7.
- 25 33. Zhang X, Shen Y, Cao Z, Zhu Y, Liu W, Wu W, et al. Carbon nanotube promotes contraction and  
26 electrical activity of neonatal cardiomyocytes by targeting sodium/calcium exchanger NCX1. *Signal*  
27 *Transduct Target Ther.* 2023;8(1):180.
- 28
- 29

## 1 **Contributors**

2 YZ, Conceptualization, Data curation, Formal analysis, Methodology, Writing-original draft; YW  
3 Conceptualization, Methodology, Writing-original draft; ZC and FL, Conceptualization, Methodology,  
4 Writing-review, and editing; JH, Conceptualization, Data curation, Funding acquisition, Writing-review,  
5 and editing. All authors critically edited the manuscript, followed by reading and approving the final  
6 version. All authors had full access to all the data in the study and had final responsibility for the  
7 decision to submit for publication.

## 8 **Data sharing statement**

9 The GWAS summary statistics for heart failure and blood pressure used in this study are deposited in  
10 the GWAS Catalog (<https://www.ebi.ac.uk/gwas/>) and the accession codes are as follows: HF  
11 (GCST009541), SBP (GCST006624), DBP (GCST006630), and PP (GCST006629). Summary-level  
12 data from Global Lipids Genetics Consortium (GLGC) for blood lipids are available as follows:  
13 <https://csg.sph.umich.edu/willer/public/glgc-lipids2021>, and additional lipids traits ( APOA1 [ieu-b-107]  
14 and APOB [ieu-b-108]) are available through the IEU Open GWAS database. Data for blood glucose  
15 can be obtained from UK Biobank-Neale lab via <http://www.nealelab.is/uk-biobank>. The pQTL  
16 summary statistics are acquired from the UK Biobank Pharma Proteomics Project (UKB-PPP) through  
17 the website <https://www.synapse.org>, and from deCODE genetics via <http://www.decode.com>.  
18 Phenome-wide summary statistics for the UK Biobank can be accessed at  
19 <https://www.leelabsg.org/resources>.

## 20 **Code availability**

21 No novel custom computer code or mathematical algorithm was employed in generating the results  
22 pivotal to the derived conclusions.

## 23 **Declaration of interests**

24 All authors declare no competing interests.

## 25 **Acknowledgements**

26 We thank Figdraw ([www.figdraw.com](http://www.figdraw.com)) for its help in creating the figures. We would like to express our  
27 gratitude to all researchers and participants involved in GWAS studies, for their generous sharing their  
28 data.

## 29 **Funding Information**

30 This work was supported by the Capital's Funds for Health Improvement and Research (2020-2-4203).

1

## 2 **Legend**

3 **Fig.1 Design schematic of the present study.** *HDL-C: high-density lipoprotein cholesterol, LDL-C:*  
4 *low-density lipoprotein cholesterol, TC: total cholesterol, TG: triglyceride, APOA1: apolipoprotein A1,*  
5 *APOB: apolipoprotein B, SBP: systolic blood pressure, DBP: diastolic blood pressure, PP: Pulse*  
6 *pressure, FG: Fasting glucose, HbA1c: Hemoglobin A1c.*

7

## 8 **Fig.2 Genetic correlation and genetic causality proportion between HF and the quantitative traits**

9 **of BL, BP, and BG.** a, The correlation heat-map shows the global genetic correlation and genetic  
10 causality proportion between HF and the quantitative traits of BL, BP, and BG. b, Chord diagram  
11 shows the local genetic correlation between HF and these traits. *LDSC: linkage disequilibrium score*  
12 *regression, HDL: high-Definition Likelihood, LCV: latent causal variable model, rg: genetic*  
13 *correlation estimate, gcp: genetic causality proportion, HF: heart failure, HDL-C: high-density*  
14 *lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol, TC: total cholesterol, TG:*  
15 *triglyceride, APOA1: apolipoprotein A1, APOB: apolipoprotein B, SBP: systolic blood pressure, DBP:*  
16 *diastolic blood pressure, PP: Pulse pressure, FG: Fasting glucose, HbA1c: Hemoglobin A1c.*

17

## 18 **Fig.3 Circular plot of multi-trait analysis of GWAS results for $HF_{GWAS}$ , $HF_{BL}$ , $HF_{BP}$ , and $HF_{BG}$ .**

19 The dots in the inner circle represent the loci (index SNV) associated with each trait. The middle part  
20 presents the genomic risk loci. The outer part presents the nearest genes to the top signals of HF, and  
21 the associated traits are indicated by different coloured squares. Genes in red denote novel loci. The  
22 details of these risk loci in the traits of BL, BP, and BG are presented in Supplementary Table 10-12.  
23 *HF: heart failure, BL: blood lipids, BP: blood pressure, BG: blood glucose.*

24

## 25 **Fig.4 Forest plot of protein targets for heart failure indicated by mendelian randomization**

26 **analysis.** The forest plot only displayed 33 specific protein targets that satisfied the statistical  
27 significance of both mendelian randomization ( $FDR.P < 0.05$ ) and colocalization ( $PP.H4 > 0.7$ ) in at least  
28 one cohort. The square symbolizes the odds ratio for mendelian randomization, while the horizontal  
29 line represents the 95% confidence interval. *UKB-PPP: UK Biobank Pharma Proteomics Project;*  
30 *deCODE: deCODE genetics; HF: heart failure; BL: blood lipids; BP: blood pressure; BG: blood*



1 *glucose; P<sub>adjusted</sub>: false discovery rate (FDR) adjusted p-value; OR: odds ratio; CI: confidence*  
2 *interval.*

3

4 **Table 1. The summary of MTAG results for heart failure.** *MTAG: multi-trait analysis of GWAS; h<sub>2</sub>:*  
5 *Observed scale heritability (LD score regression); Se: standard error; gcov<sub>int</sub>: genetic covariance*  
6 *intercept; λ<sub>GC</sub>: the genomic control inflation factor based on the median; maxFDR: maximum FDR;*  
7 *CADD: combined annotation dependent depletion.*

8

## 9 **Supplementary Materials**

10 **Supplementary Methods**

11 **Supplementary Results**

12 **Supplementary Discussion**

13 **Supplementary Tables 1-49:** Table of contents, S1-S49.

14 **Supplementary Fig. 1 Wayne diagrams of the results indicated by gene base and**  
15 **transcriptome-wide association analyses.** a, Plots shows the results of gene-mapping analysis. b,  
16 Plots shows the results of MAGMA and TWAS analysis. *MAGMA: multi-marker analysis of genomic*  
17 *annotation, TWAS: transcriptome-wide association analysis.*

18 **Supplementary Fig. 2 Significantly enriched in GO and KEGG gene sets of heart failure**  
19 **indicated by MAGMA analysis.** a, gene-set enrichment of HF<sub>BL</sub>. b, gene-set enrichment of HF<sub>BP</sub>. c,  
20 gene-set enrichment of HF<sub>BG</sub>. *GO: Gene Ontology, KEGG: Kyoto Encyclopedia of Genes and*  
21 *Genomes, MAGMA: multi-marker analysis of genomic annotation, HF: heart failure, BL: blood lipids,*  
22 *BP: blood pressure, BG: blood glucose.*


23 **Supplementary Fig. 3 Enrichment of tissue specificity associated with heart failure.** a, associated  
24 tissues of HF<sub>BL</sub>. b, associated tissues of HF<sub>BP</sub>. c, associated tissues of HF<sub>BG</sub>. *HF: heart failure, BL:*  
25 *blood lipids, BP: blood pressure, BG: blood glucose.*

26 **Supplementary Fig. 4 Enrichment of cell-type specificity associated with heart failure.** a,  
27 associated cell types of HF<sub>BL</sub>. b, associated cell types of HF<sub>BP</sub>. c, associated cell types of HF<sub>BG</sub>. *HF:*  
28 *heart failure, BL: blood lipids, BP: blood pressure, BG: blood glucose.*

29 **Supplementary Fig. 5 Enrichment of similar phenotype specificity associated with heart failure.** a,  
30 associated similar phenotypes of HF<sub>BL</sub>. b, associated similar phenotypes of HF<sub>BP</sub>. c, associated similar

- 1 phenotypes of HF<sub>BG</sub>. *HF: heart failure, BL: blood lipids, BP: blood pressure, BG: blood glucose.*
- 2 **Supplementary Fig. 6 The exploration of non-HF pleiotropic or side effects for the protein targets**
- 3 **from UKB-PPP.** Manhattan plot utilizes black circles to highlight the statistically significant results of
- 4 the FDR correction. *UKB-PPP: UK Biobank Pharma Proteomics Project.*
- 5 **Supplementary Fig. 7 The exploration of non-HF pleiotropic or side effects for the protein targets**
- 6 **from deCODE.** Manhattan plot utilizes black circles to highlight the statistically significant results of
- 7 the FDR correction. *deCODE: deCODE genetics.*

## Data source and data extraction



## Genetic correlation and genetic causality proportion

### Global genetic correlation

LD score regression(LDSC) & High-Definition Likelihood(HDL)

### Local genetic correlation

Local analysis of [co]variant association (LAVA)

### Genetic causality proportion

Latent causal variable (LCV)

## Multi-trait association analysis

### Multi-trait analysis of GWAS (MTAG)

HF <input checked="" type="checkbox"/>	BL: APOA1 <input checked="" type="checkbox"/>	APOB <input type="checkbox"/>	HDL-C <input checked="" type="checkbox"/>	LDL-C <input type="checkbox"/>	TC <input type="checkbox"/>	TG <input checked="" type="checkbox"/>
HF <input checked="" type="checkbox"/>	BP: SBP <input checked="" type="checkbox"/>	DBP <input checked="" type="checkbox"/>	PP <input checked="" type="checkbox"/>			
HF <input checked="" type="checkbox"/>	BG: FG <input checked="" type="checkbox"/>	HbA1c <input checked="" type="checkbox"/>				

## Characterizing heart failure-associated loci


Characterize genomic risk loci and candidate significant SNVs

Functional mapping and annotation

## Identification of potential pleiotropic risk loci

### Hypothesis prioritization for multi-trait colocalization (HyPrColoc)

HF <sub>BL</sub> <input checked="" type="checkbox"/>	APOA1 <input checked="" type="checkbox"/>	HDL-C <input checked="" type="checkbox"/>	TG <input checked="" type="checkbox"/>
HF <sub>BP</sub> <input checked="" type="checkbox"/>	SBP <input checked="" type="checkbox"/>	DBP <input checked="" type="checkbox"/>	PP <input checked="" type="checkbox"/>
HF <sub>BG</sub> <input checked="" type="checkbox"/>	FG <input checked="" type="checkbox"/>	HbA1c <input checked="" type="checkbox"/>	



## Gene prioritization and gene-sets enrichment

**Gene mapping analysis** Positional mapping  eQTL mapping  3D Chromatin Interaction mapping

**Gene-based analysis** Multi-marker analysis of genomic annotation (MAGMA)

**Transcriptome-wide association analysis (TWAS)** GTEx v8: Whole Blood, Artery - Aorta & Coronary, Heart - Atrial Appendage & Left Ventricle

**Gene-set analysis** GO & KEGG

## Phenotype-cell-gene association analysis

**Tissues/cell types specificity** 54 human tissues/2,214 human single cell types

**Similar phenotypes specificity** 1871 phenotypes


## Genomics-driven drug discovery

**Repositioning for current use or developed in the past drugs** Genome for REPositioning drugs (GREP)


**Therapeutic protein targets for heart failure** Proteome-wide mendelian randomisation and colocalization analysis (UKB-PPP & deCODE)

**Pleiotropic or side effects for protein targets** Phenome-wide mendelian randomisation analysis (1400 non-HF traits from UK Biobank)

A



B



- HF-Raw
- HF-BL
- HF-BP
- HF-BG



## UKB-PPP

## deCODE

Gene	P.adjusted	OR (95%CI)
PLTP	2.51e-23	0.968(0.963-0.974)
CELSR2	5.97e-18	0.965(0.958-0.973)
LPL	1.94e-12	0.952(0.941-0.964)
CTRL	3.49e-09	0.865(0.830-0.902)
HYOU1	1.79e-05	1.038(1.024-1.053)
GSTM4	4.82e-05	1.020(1.012-1.027)
APOA2	6.55e-04	0.915(0.881-0.950)
NCAN	0.001	1.037(1.021-1.054)
ATRAID	0.002	0.980(0.972-0.989)
PLG	0.037	0.981(0.971-0.992)
SH2B3	2.73e-08	1.135(1.094-1.178)
FES	2.50e-07	0.941(0.923-0.959)
CELSR2	7.72e-06	0.978(0.971-0.986)
TJAP1	4.36e-04	0.868(0.820-0.919)
ZBTB17	0.001	1.138(1.078-1.202)
NPPB	0.003	0.969(0.956-0.983)
NADK	0.003	0.978(0.968-0.988)
SPINK8	0.004	1.016(1.009-1.024)
WASHC3	0.004	1.068(1.036-1.101)
DLL1	0.014	0.972(0.959-0.986)
CELSR2	2.02e-04	0.978(0.970-0.986)
DLK1	0.001	0.980(0.972-0.988)

0.8 1.2

Gene	P.adjusted	OR (95%CI)
APOA4	1.52e-14	1.111(1.085-1.138)
LILRA5	9.30e-06	1.020(1.013-1.027)
KPNA2	7.47e-05	1.120(1.074-1.169)
GSTA1	0.003	0.983(0.976-0.990)
INHBC	0.011	1.007(1.004-1.010)
GSTM4	0.015	1.011(1.006-1.017)
NMT1	1.63e-07	1.199(1.134-1.266)
ALDH2	3.04e-06	1.104(1.068-1.142)
CSK	3.59e-04	1.109(1.064-1.155)
HEXIM2	0.002	1.073(1.041-1.106)
NPPB	0.003	0.939(0.913-0.965)
NADK	0.003	0.956(0.936-0.975)
ULK3	0.006	1.071(1.037-1.105)
NPPA	0.012	0.920(0.883-0.959)
PFKM	0.005	1.039(1.022-1.056)
ALDH6A1	0.030	0.931(0.899-0.963)

0.8 1.2

HF<sub>BL</sub>

HF<sub>BL</sub>

HF<sub>BP</sub>

HF<sub>BP</sub>

HF<sub>BG</sub>

HF<sub>BG</sub>

---

Trait	liability-scale $h^2$ (Se)	$\lambda$ GC	Mean $\text{Chi}^2$	gcov_int (Se)	maxFDR_MTAG	N_sample size	N_risk loci	N_novel risk loci	N_genome-wide significant SNVs	N_exons	N_CADD score>12.37
HFGWAS	0.0304 (0.0024)	1.127	1.159	1.006 (0.007)	NA	964057	11	-	736	20	40
HFBP	0.0618 (0.0032)	1.114	1.259	0.826 (0.010)	0.046	1366841	93	85	4188	117	186
HFBG	0.0558 (0.0026)	1.118	1.227	0.862 (0.009)	0.032	1243259	48	41	1930	41	78
HFBG	0.0395 (0.0022)	1.127	1.189	0.933 (0.008)	0.029	1240601	40	31	934	13	28

---